MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a clinical-stage biotechnology company with a fully-human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. MBVX’s lead antibody is directed at an antigen target expressed on more than 90% of pancreatic cancers and a significant amount of other GI and lung cancers, making the antibody potentially broadly applicable to a wide variety of patients suffering from difficult to treat cancers. The Company has collaborations with Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, Honor Health and Imaging Endpoints. MabVax has treated 50 patients in Phase I clinical studies with either its therapeutic antibody, MVT-5873, or its PET imaging diagnostic product, MVT-2163, and results of these trials should be published by mid-year 2017. Additionally, a Phase I clinical study for MBVX’s radioimmunotherapy product designated as MVT-1075 has been authorized to proceed by the FDA and will soon commence with patient enrollment.